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Effect of N-acetylcysteine on pain in daily life in patients with
sickle cell disease: a randomised clinical trial
The hallmarks of sickle cell disease (SCD) include the acute
vaso-occlusive, painful crises (VOC), associated with frequent
hospitalizations. SCD-related pain is reported on 17% of
observed days, significantly hampering patients in their daily
lives (van Tuijn et al, 2017).
Oxidative stress has been demonstrated to play a pivotal
role in the pathophysiology of SCD, generated by factors
such as haemolysis and ischaemia-reperfusion injury. Reac-
tive oxygen species promote a vicious circle of additional
haemolysis, inflammation, hypercoagulability and endothelial
dysfunction.(Nur et al, 2011) Therefore, antioxidants may be
of great therapeutic potential in SCD, by simultaneously
affecting multiple pathophysiological processes.
The antioxidant N-acetylcysteine (NAC) has been demon-
strated to exert a broad range of beneficial effects in SCD,
improving markers of oxidative stress and haemolysis, and
possibly even the VOC rate (Pace et al, 2003; Nur et al,
2012; €Ozpolat et al, 2014).
NAC is a safe, inexpensive drug that has been used for
years for various indications, making it an accessible treat-
ment for the majority of SCD patients in the developing
world. We here report the results of an investigator-initiated,
randomised, placebo-controlled, double-blind trial (NAC
trial), which aimed to evaluate the effect of NAC on the fre-
quency of SCD-related pain in daily life in patients with
SCD (NCT01849016).
This study was initiated in four centres in the Netherlands
in 2012, and expanded to six centres in Belgium and one
centre in the United Kingdom in 2015. Patients were eligible
for participation if they were ≥12 years old, had either HbSS,
HbSC, HbSb⁰ or HbSb⁺ disease, and a history of ≥1 VOC
per year. Patients using hydroxycarbamide were eligible to
participate (see Table SI for complete criteria). Upon ran-
domization, patients were randomly assigned to receive
either oral NAC 600 mg twice daily or placebo. Total treat-
ment duration was 6 months.
The primary end point was the rate of SCD-related pain
days per patient year, as measured by a daily pain diary. Sec-
ondary outcomes included the rate per patient year of days
with VOC, admission days for VOC, hospitalizations for
VOC and days with home analgesic use.
The primary analysis of this study was limited to patients
with a minimal completed study observation time of
110 days within the total follow-up of 6 months [modified
intention-to-treat analysis (mITT)]. An additional, pre-speci-
fied per-protocol analysis was performed on a subset of
Table I. Baseline characteristics of SCD
patients in the modified intention-to-treat pop-
ulation. SCD patients with ≥110 study observa-
tion days available, N = 67. Additional baseline






Age in years – mean  SD 284  89 296  84
Age category – n (%)
12–17 years 6 (15) 2 (7)
≥18 years 34 (85) 25 (93)
Female sex – n (%) 26 (65) 14 (52)
Haemoglobin genotype – n (%)
HbSS/HbSb0 29 (73) 17 (63)
HbSC/HbSb+ 11 (28) 10 (37)
Ethnic origin – n (%)
Latin-America/Caribbean 17 (43) 12 (44)
Africa 23 (58) 15 (56)
Consent for text message service – n (%) 34 (85) 20 (74)
Use of hydroxycarbamide – n (%) 16 (40) 12 (44)
Clinical history over past 3 years – median (IQR)
Number of VOC 11 (6-20) 8 (5-15)
Number of hospital admissions for VOC 3 (1-6) 3 (1-6)
IQR, interquartile range; NAC, N-acetylcysteine; SCD, sickle cell disease; SD, standard devia-
tion; VOC, vaso-occlusive crisis.
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patients with ≥80% adherence to the assigned study medica-
tion, as checked by tablet counts.
Event rates per treatment arm were compared by Poisson
regression analysis.
Additional information on the study methods is available
in the online supporting information.
A total of 96 patients were randomised (Fig S1) between
April 2013 and November 2015. Of the 90 patients, 40 in the
placebo group and 27 in the NAC group were included in the
mITT analysis (≥110 observation days, Tables I, SII, and III).
In the mITT population, the rate of SCD-related pain days
per patient year was comparable between both treatment arms
(Table II). In addition, NAC had no effect on the secondary
outcomes of this study (Tables II and SIV–VI). This was consis-
tent in sensitivity analyses in the total study cohort (Table SVII)
and patients with ≥80 observation days (data not shown).
Only 70% of patients in the placebo group, and 56% in
the NAC group returned all study medication bottles for
tablet counts. Of these, the percentage of patients that were
adherent to the study treatment (≥80% tablets used) was
similar in both treatment arms (50% in placebo, 53% in
NAC group). A per-protocol analysis was performed on this
adherent subset (N = 27, Table SVIII). Here, we observed a
significantly lower rate of VOC days in the NAC arm as
compared to placebo: 205 vs. 401 events per patient year
(Table SIX, rate ratio 050, 95% CI 027–094). The rate of
hospital admission days per patient year and the risk of a
first VOC appeared to be lower in the NAC arm, but this
did not reach statistical significance (Tables SIV and SIX). In
addition, haemoglobin and erythrocyte levels increased sig-
nificantly after 3 months of study treatment (T3) in the
NAC arm as compared to placebo (Table SX).
Significantly more patients in the NAC group reported
gastro-intestinal events, including nausea, diarrhoea or
abdominal discomfort (Table SXI, P = 0006). All serious
adverse events are listed in Table SXII.
In conclusion, treatment with oral NAC was not of clinical
benefit over placebo in the mITT analysis of this study.
These findings are in contrast with previous studies with
NAC, and trials evaluating other antioxidants (Daak et al,
2013; Niihara et al, 2014). Importantly, adherence was poor
in this study – a notorious issue in SCD (Walsh et al, 2014).
Table II. Primary and secondary efficacy end points in the modified intention-to-treat population. SCD patients with ≥110 study observation








Total length of follow-up – patient-year 183 121
Pain days
Patients with events – n (%) 39 (98) 26 (96)
Total events 1124 746
Event rate per patient-year 614 616 098 (054–178) 0.96
Days with VOC
Patients with events – n (%) 34 (85) 23 (85)
Total events 521 332
Event rate per patient-year 285 274 098 (052–184) 0.94
Admission days
Patients with events – n (%) 14 (35) 9 (33)
Total events 129 103
Event rate per patient-year 71 85 123 (036–420) 0.75
Number of admissions
Patients with events – n (%) 14 (35) 9 (33)
Total events 23 15
Event rate per patient-year 13 12 096 (042–219) 0.93
Days with home analgesic use
Duration of pain day follow-up – patient-year 27 18
Patients with events – n (%) 37 (93) 25 (93)
Total events 660 528
Event rate per patient-year 2423 2999 118 (089–157) 0.25
Mean difference (95% CI)
Maximum pain intensity on pain days – mean† 437 420 017 (054–087) 0.64
Maximum pain intensity on VOC days – mean‡ 489 486 003 (088–095) 0.94
CI, confidence interval; NAC, N-acetylcysteine; SCD, sickle cell disease; VOC, vaso-occlusive crisis.
*Placebo arm is the reference group. Adjusted for the covariate HU use at baseline.
†Limited to patients with ≥3 pain days; placebo N = 35, NAC N = 24, and excluding hospitalization days.
‡Limited to patients with ≥3 VOC days; placebo N = 27, NAC N = 20, and excluding hospitalization days.
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Per-protocol analysis in adherent patients did suggest a
reduction of days with VOC in the NAC treatment arm, and
trends of improvement in other parameters.
Various lessons can be learned for future studies. By
including patients with only 1 VOC per year, a subgroup
with relatively mild disease may have been less inclined to
maintain good adherence. In retrospect, the patient-centred
primary endpoint of SCD-related pain in daily life may not
have been the most sensitive outcome for this study, as this
definition may include chronic pains.(van Tuijn et al, 2017)
Significantly more patients in the NAC arm reported gastro-
intestinal adverse events, possibly adding to the higher drop-
out rate here. Notably, one patient experienced a gastro-
intestinal perforation after 2 weeks of NAC use. As NAC has
proven to be safe in many clinical studies, it is most likely
that this patient suffered from gastro-intestinal, vaso-occlu-
sive ischaemia (Gardner & Jaffe, 2016). Lastly, the dosage of
NAC in this study may have been relatively low to elicit
strong clinical effects. Previous pilot studies with NAC
appeared to demonstrate better effects at a higher dose, yet
potentially also more adverse events. Individual dose escala-
tion up to a highest tolerable dose could be a solution here.
These findings provide an important opportunity for fur-
ther research. We are currently performing additional blood
sample analysis of pathophysiological markers to corroborate
our clinical findings. Encouragingly, the therapeutic potential
of intravenous, high-dose administration of NAC during
VOC is currently being pursued (NCT01800526).
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Data S1. Methods.
Fig S1. CONSORT flow diagram.
Table SI. Inclusion and exclusion criteria of the NAC
trial.
Table SII. Comparison of baseline characteristics between
patients included in the modified intention-to-treat (mITT)
population with ≥110 observation days, and patients
excluded from this population with <110 observation days.
Table SIII. Additional baseline characteristic of patients in
the modified intention-to-treat population (N = 67).
Table SIV. Time to first VOC and time to first hospital
admission for VOC.
Table SV. Mean change in health-related quality of life in
adult patients only, compared to baseline (T0) in the inten-
tion-to-treat population (N = 67).
Table SVI. Mean change in general laboratory parameters
compared to baseline (T0) in the intention-to-treat popula-
tion (N = 67).
Table SVII. Sensitivity analysis of primary and secondary
efficacy end points in total study cohort (with ≥1 study
observation day available, N = 85).
Table SVIII. Baseline characteristics of patients in the per
protocol population (patients with ≥110 study observation
days available and ≥80% adherence, N = 27).
Table SIX. Primary and secondary efficacy end points in
the per protocol population.
Table SX. Mean change in laboratory parameters com-
pared to baseline (T0) in the per protocol population (pa-
tients with ≥110 study observation days available and ≥80%
adherence, N = 27).
Table SXI. Adverse events in total study cohort (N = 96).
Table SXII. Serious adverse events in total study cohort.
Table SXIII. Exploratory subgroup analyses of the main
outcomes in the intention-to-treat population for genotype,
use of hydroxycarbamide and history of hospital admissions
(N = 67).
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